Intensity Therapeutics, Inc. develops intratumoral cancer therapies using proprietary non-covalent drug-conjugation technology. Its lead investigational product candidate, INT230-6, is designed for direct injection into tumors and combines cisplatin, vinblastine sulfate, and the SHAO diffusion and cell-penetration enhancer to disperse cytotoxic agents within cancer cells.
Recurring company news covers INT230-6 clinical development, including the INVINCIBLE-4 study in early-stage operable triple negative breast cancer and the INVINCIBLE-3 study in selected soft tissue sarcoma subtypes. Updates also address financial results, cash resources, intellectual-property protection for the intratumoral technology platform, at-the-market financing activity, Nasdaq listing compliance, and capital-structure actions affecting the company’s common stock.
Intensity Therapeutics (Nasdaq: INTS) reported third-quarter financial results and resumed enrollment activities in both clinical trials of cancer treatment INT230-6. Phase 3 INVINCIBLE-3 enrollment activities restarted at limited U.S. sites; faster enrollment depends on additional funding. Phase 2 INVINCIBLE-4 enrollment and treatment resumed in July after a dosing amendment addressing localized skin irritation. The company targets enrollment completion by year-end 2027 and a safety-review update in the first quarter of 2027.
Preliminary INVINCIBLE-4 results in 14 patients showed 71% pathological complete response, meaning no live cancer at surgery, with INT230-6 before standard treatment versus 42% with standard treatment alone. Third-quarter net loss widened to $3.544 million from $2.671 million. Cash was $8.494 million at September 30, versus $11.921 million at year-end 2025. Third-quarter share sales generated $1.5 million net.
Intensity Therapeutics (Nasdaq: INTS) will report third-quarter 2026 financial results before the market opens on November 5, 2026.
The results cover the quarter ended September 30, 2026. Management will host a conference call and live webcast at 8:00 a.m. Eastern time that day to review the results and provide a corporate update. An archived webcast will be available shortly after the call ends.
Intensity Therapeutics (INTS) reported pathological complete responses in five of seven patients receiving INT230-6 plus standard-of-care treatment in its INVINCIBLE-4 study. The randomized, open-label phase 2 trial evaluates early-stage, operable triple-negative breast cancer. The response rate was 71% (95% confidence interval 29–96%), meaning no invasive cancer remained in the breast or affected lymph nodes.
All seven patients showed tumor tissue death after one or two injections. Pre-surgery MRI showed four complete and three partial responses after neoadjuvant immuno-chemotherapy, treatment given before surgery. Dose-limiting local skin reactions prompted a protocol amendment to one injection at a lower drug-volume-to-tumor-volume ratio. The Swiss Cancer Institute will present the first seven Cohort A patients' data through an ESMO ePoster.
Intensity Therapeutics (INTS) will participate in the H.C. Wainwright 28th Annual Global Investment Conference in New York, held September 14–16, 2026.
The company’s presentation will be available on-demand starting at 7:00 a.m. ET on September 11, 2026, via a webcast accessible through its investor relations website and the provided conference link. The webcast replay will remain archived for about 90 days. President and CEO Lewis H. Bender will be available for one-on-one investor meetings during the conference, which require registration through the H.C. Wainwright conference website.
Intensity Therapeutics (Nasdaq: INTS) reported second quarter 2026 results and a business update. Research and development expenses were $1.8 million versus $1.5 million a year ago, and general and administrative expenses were $1.3 million versus $1.2 million. Net loss widened to $3.0 million from $2.5 million, with six‑month net loss at $5.4 million versus $5.9 million in 2025.
As of June 30, 2026, cash and cash equivalents were $9.5 million. The company established a $60 million at‑the‑market facility in March 2026, raising net proceeds of $1.6 million in Q2 and an additional $1.3 million thereafter. Intensity initiated activities to resume enrollment at selected U.S. sites in its Phase 3 INVINCIBLE‑3 soft tissue sarcoma study under an FDA‑reviewed amended protocol. In the Phase 2 INVINCIBLE‑4 TNBC study, patient treatment restarted with an updated dosing regimen; early data from 14 patients showed a 71% pathological complete response rate with INT230‑6 plus standard of care versus 42% with standard of care alone and a 44% reduction in grade 3 adverse events.
Intensity Therapeutics (Nasdaq: INTS), a late-stage clinical biotechnology company developing novel intratumoral cancer therapies using its proprietary non-covalent conjugation technology, will report second quarter 2026 financial results for the period ended June 30, 2026 before the market opens on August 11, 2026.
According to Intensity Therapeutics, company management will host a conference call and live webcast at 8:00 a.m. Eastern Time on August 11 to review the results and provide a corporate update. Investors can join via domestic dial-in (866) 652-5200, international dial-in (412) 317-6060, or the webcast URL provided. An archived webcast replay will be available shortly after the call.
Intensity Therapeutics (Nasdaq: INTS) announced the restart of patient treatment and first new dosing of INT230-6 in the randomized, open-label Phase 2 INVINCIBLE-4 presurgical triple-negative breast cancer (TNBC) trial in Switzerland. The study compares INT230-6 given before standard-of-care neoadjuvant immuno-chemotherapy (SOC) versus SOC alone in two cohorts.
The primary endpoint is pathological complete response (pCR) in the primary tumor and affected lymph nodes, with cohorts evaluated against a null hypothesis pCR rate of ≤0.6. The trial reopened after a pause to assess skin irritation, following a March 2026 protocol amendment to use a slightly lower drug-to-tumor volume ratio and a single INT230-6 injection. Before the pause, 14 patients were treated; those receiving INT230-6 prior to SOC reported a favorable trend toward fewer grade 3 or higher and immune-related adverse events versus SOC alone. The study is expected to enroll an additional 47 patients in Switzerland and France.
Intensity Therapeutics (Nasdaq: INTS) issued a mid‑year 2026 update on late‑stage development of INT230-6, its intratumoral cancer therapy. Key items include progress in Phase 2/3 breast cancer and Phase 3 soft tissue sarcoma trials, peer‑reviewed data in advanced tumors, active partnering discussions and expanded funding capacity via a $60 million at‑the‑market facility.
More than 200 patients have received INT230-6 in completed studies, and preliminary presurgical triple‑negative breast cancer data showed higher pathological complete responses and fewer severe adverse events versus standard of care.
Intensity Therapeutics (Nasdaq: INTS), a late-stage clinical biotechnology company developing proprietary intratumoral cancer therapies, has been named Cancer Treatment Technology Innovator of the Year 2026 – USA in GHP Magazine's Healthcare & Pharmaceutical Awards.
The judging panel cited Intensity's non-covalent drug-conjugation platform, encouraging clinical outcomes in advanced cancers with few options, and INT230-6's potential to reduce tumor burden and trigger systemic anticancer immune responses with limited off-target toxicity.
Intensity Therapeutics (Nasdaq: INTS) reported Q1 2026 results and a corporate update. Cash and cash equivalents were $10.2 million as of March 31, 2026. Preliminary INVINCIBLE-4 results showed pCR 71.4% with INT230-6 versus 33% SOC in a small sample, and 44% fewer grade ≥3 adverse events. Swissmedic approved resuming enrollment on March 26, 2026; the company plans to resume INVINCIBLE-4 enrollment in Q2 2026 and limited INVINCIBLE-3 U.S. sites by Q3 2026. First-quarter R&D was $1.2M, G&A $1.3M, and net loss $2.4M. A $60M ATM facility was established in March 2026.